

*Anderson et al.
Serial No.: 09/880.019
Page 2 of xx*

Remarks/Arguments

In response to the Rejection mailed July 13, 2004, Applicants have attached three terminal disclaimer forms and present the following remarks

Claims 61-66 were rejected under the doctrine of obviousness-type double patenting as unpatentable over claims 1-17 of U.S. Patent 6,713,309. Applicants have filed a terminal disclaimer of this application to the period for U.S. Patent 6,713,309 thereby overcoming this rejection.

Claims 55-66 were provisionally rejected under the doctrine of obviousness-type double patenting as unpatentable over claims 1-9 and 46-50 of copending application No. 10/061,969. Applicants have filed a terminal disclaimer of this application to the period for application No. 10/061,969, thereby overcoming this rejection.

Claims 55-66 were provisionally rejected under the doctrine of obviousness-type double patenting as unpatentable over claims 16, 18, 22, 24, and 81-87 of copending application No. 09/774,794. Applicants have filed a terminal disclaimer of this application to the period for application No. 09/774,794, thereby overcoming this rejection.


In view of the terminal disclaimers and comments above, the rejections have been overcome. Reconsideration, withdrawal of the rejections and early indication of allowance are respectfully requested. If any issues remain, the examiner is encouraged to telephone the undersigned.

Please charge a terminal disclaimer fee of \$55.00 to deposit account 500933 under 37 CFR 1.321. Applicants are a small entity under section 1.20(d).

Anderson et al.
Serial No.: 09/880.019
Page 3 of xx

If needed, applicants petition for an extension of time under the provisions of 37 CFR 1.136(a) for sufficient time to accept this response. The commissioner hereby is authorized to charge payment of any fees under 37 CFR § 1.17, which may become due in connection with the instant application or credit any overpayment to Deposit Account No.500933.

Respectfully submitted,



Date: October 13, 2004

John E. Tarcza
Reg. No. 33,638

Enclosures: Three terminal disclaimer forms

John E. Tarcza
Intellectual Property Advisor
Large Scale Biology Corporation
3333 Vaca Valley Parkway, Suite 1000
Vacaville, CA 95688
301-371-7740 tel.
301-371-7745 Fax.
E-MAIL john.tarcza@lsbc.com